Çubukcu, ErdemCanhoroz, MustafaÖlmez, Ömer FatihKanat, ÖzkanKurt, EnderErol, MuharremÇubukcu, SinemYorulmaz, NadideBayram, SamiEvrensel, TürkkanManavoğlu, Osman2024-09-192024-09-192014-09-011309-0720https://doi.org/10.4328/JCAM.1469https://www.webofscience.com/wos/woscc/full-record/WOS:000215566500018https://hdl.handle.net/11452/44927Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.eninfo:eu-repo/semantics/openAccessNonsmall cell lung cancerAdjuvant chemotherapyCisplatinGeneral & internal medicineArticle0002155665000184144165510.4328/JCAM.1469